Valneva SE (NASDAQ:VALN - Get Free Report) shares were up 2.3% on Friday . The company traded as high as $7.45 and last traded at $7.42. Approximately 6,542 shares were traded during trading, a decline of 75% from the average daily volume of 25,882 shares. The stock had previously closed at $7.25.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on the stock. Guggenheim dropped their price target on shares of Valneva from $17.00 to $15.00 and set a "buy" rating for the company in a research note on Monday. HC Wainwright reaffirmed a "buy" rating and set a $17.00 target price on shares of Valneva in a report on Friday.
Read Our Latest Report on Valneva
Valneva Price Performance
The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The business's 50-day simple moving average is $6.45 and its two-hundred day simple moving average is $5.59. The firm has a market cap of $574.52 million, a price-to-earnings ratio of -54.38 and a beta of 1.93.
Valneva (NASDAQ:VALN - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.32). The firm had revenue of $56.48 million for the quarter, compared to analyst estimates of $55.64 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. As a group, research analysts expect that Valneva SE will post 0.13 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Valneva stock. Wells Fargo & Company MN increased its holdings in shares of Valneva SE (NASDAQ:VALN - Free Report) by 14.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 246,766 shares of the company's stock after purchasing an additional 30,859 shares during the period. Wells Fargo & Company MN owned approximately 0.30% of Valneva worth $1,079,000 at the end of the most recent quarter. 11.39% of the stock is currently owned by institutional investors.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Recommended Stories
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
